DK1593387T3 - Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser - Google Patents

Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser

Info

Publication number
DK1593387T3
DK1593387T3 DK05006494T DK05006494T DK1593387T3 DK 1593387 T3 DK1593387 T3 DK 1593387T3 DK 05006494 T DK05006494 T DK 05006494T DK 05006494 T DK05006494 T DK 05006494T DK 1593387 T3 DK1593387 T3 DK 1593387T3
Authority
DK
Denmark
Prior art keywords
compositions
disorders
treatment
interpersonal
environment
Prior art date
Application number
DK05006494T
Other languages
English (en)
Inventor
Tony Marcel
Francois Rougeon
Catherine Rougeot
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK1593387T3 publication Critical patent/DK1593387T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Radiation-Therapy Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK05006494T 1999-06-23 2000-06-22 Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser DK1593387T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14056399P 1999-06-23 1999-06-23
PCT/EP2000/006259 WO2001000221A2 (en) 1999-06-23 2000-06-22 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders

Publications (1)

Publication Number Publication Date
DK1593387T3 true DK1593387T3 (da) 2009-03-02

Family

ID=22491816

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05006494T DK1593387T3 (da) 1999-06-23 2000-06-22 Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser
DK00947924T DK1185294T3 (da) 1999-06-23 2000-06-22 Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK00947924T DK1185294T3 (da) 1999-06-23 2000-06-22 Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser

Country Status (14)

Country Link
US (2) US7387778B2 (da)
EP (2) EP1185294B1 (da)
JP (1) JP2003512302A (da)
CN (1) CN1189211C (da)
AT (2) ATE414529T1 (da)
AU (1) AU6154700A (da)
CA (1) CA2376935A1 (da)
CY (1) CY1108745T1 (da)
DE (2) DE60040878D1 (da)
DK (2) DK1593387T3 (da)
ES (2) ES2238299T3 (da)
NZ (1) NZ516477A (da)
PT (2) PT1185294E (da)
WO (1) WO2001000221A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
ATE414529T1 (de) 1999-06-23 2008-12-15 Pasteur Institut Zusammensetzungen zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
DE60018085T2 (de) * 2000-12-22 2005-07-07 Institut Pasteur Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden
BR122018074353B8 (pt) 2003-01-28 2023-05-02 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2390075T3 (es) 2004-03-19 2012-11-06 Institut Pasteur Péptidos derivados de la proteína BPLP humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP5788788B2 (ja) * 2008-04-07 2015-10-07 アンスティテュ パストゥールＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ エンケファリンを分解するエクトペプチダーゼを強力に阻害するオピオルフィンペプチド誘導体
FR2931362B1 (fr) 2008-05-26 2017-08-18 Pasteur Institut L'opiorphine pour une utilisation en tant que psychostimulant.
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
CA2645452A1 (en) * 2008-11-28 2010-05-28 Institut Pasteur Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker
JP5964589B2 (ja) 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤およびその使用方法
DE102009039655B3 (de) 2009-09-02 2011-03-31 ITT Mfg. Enterprises, Inc., Wilmington UV-Desinfektionseinrichtung für Abwasser und Trinkwasser mit einer Reinigungsvorrichtung
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
GB201607814D0 (en) 2016-05-04 2016-06-15 5D Health Prot Group Ltd Anti-microbial compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327966D0 (en) * 1983-10-19 1983-11-23 Nyegaard & Co As Chemical compounds
FR2637600B1 (fr) * 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
US5589189A (en) * 1994-09-14 1996-12-31 Nexstar Pharmaceuticals, Inc. Liposome dispersion
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
ATE414529T1 (de) 1999-06-23 2008-12-15 Pasteur Institut Zusammensetzungen zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
DE60018085T2 (de) 2000-12-22 2005-07-07 Institut Pasteur Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden

Also Published As

Publication number Publication date
ATE291927T1 (de) 2005-04-15
PT1593387E (pt) 2009-03-18
CN1356906A (zh) 2002-07-03
EP1185294B1 (en) 2005-03-30
DE60019106D1 (de) 2005-05-04
US20030186870A1 (en) 2003-10-02
US7387778B2 (en) 2008-06-17
JP2003512302A (ja) 2003-04-02
WO2001000221A3 (en) 2001-05-03
WO2001000221A2 (en) 2001-01-04
DE60040878D1 (de) 2009-01-02
PT1185294E (pt) 2005-08-31
ES2238299T3 (es) 2005-09-01
US20030078200A1 (en) 2003-04-24
CY1108745T1 (el) 2014-04-09
ATE414529T1 (de) 2008-12-15
CN1189211C (zh) 2005-02-16
EP1593387A1 (en) 2005-11-09
ES2315753T3 (es) 2009-04-01
AU6154700A (en) 2001-01-31
EP1593387B1 (en) 2008-11-19
DK1185294T3 (da) 2005-08-01
EP1185294A2 (en) 2002-03-13
CA2376935A1 (en) 2001-01-04
DE60019106T2 (de) 2006-02-16
NZ516477A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
CY1108745T1 (el) Πεπτιδια δια τη θεραπευτικη αγωγη κακης συμπεριφορας μεταξυ προσωπων
WO2004019884A3 (en) Agents and methods for enhancing bone formation
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
GB0223040D0 (en) Therapeutic compounds
ATE325612T1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
IL163026A (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
CY1108808T1 (el) Ενωσεις μοτιλιδης
SG157231A1 (en) Substituted p-diaminobenzene derivatives
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
CY1106409T1 (el) Παραγωγα κινολινης
DK1747220T3 (da) Substituerede 1H-pyrrolo[3,2-B, 3,2-C og 2,3-C]pyridin-2-carboxamider og relaterede analoger som inhibitorer af casein kinase I epsilon
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
TR200200278T2 (tr) Kalsilitik bileşimler
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.